• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline.2019年非重症和重症冠状病毒病患者的治疗:循证指南
CMAJ. 2020 May 19;192(20):E536-E545. doi: 10.1503/cmaj.200648. Epub 2020 Apr 29.
2
Recommendations for caring for patients with severe and nonsevere COVID-19.关于照顾重症和非重症 COVID-19 患者的建议。
Ann Intern Med. 2020 Jul 21;173(2):JC3. doi: 10.7326/ACPJ202007210-004.
3
How likely are COVID-19 interventions to benefit the sickest patients?新冠疫情干预措施对病情最严重的患者产生益处的可能性有多大?
Intensive Care Med. 2020 Jul;46(7):1441-1444. doi: 10.1007/s00134-020-06131-1. Epub 2020 Jun 9.
4
Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review.新冠疫情早期发布的临床指南的范围、质量和包容性:快速综述。
BMJ. 2020 May 26;369:m1936. doi: 10.1136/bmj.m1936.
5
Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.对于严重新型冠状病毒病患者的皮质类固醇治疗。
Eur Rev Med Pharmacol Sci. 2020 Aug;24(15):8194-8201. doi: 10.26355/eurrev_202008_22508.
6
Our recommendations for acute management of COVID-19.我们对新型冠状病毒肺炎急性处理的建议。
Crit Care. 2020 May 8;24(1):207. doi: 10.1186/s13054-020-02930-6.
7
COVID-19: Transmission, prevention, and potential therapeutic opportunities.新型冠状病毒肺炎:传播、预防和潜在治疗机会。
Clin Chim Acta. 2020 Sep;508:254-266. doi: 10.1016/j.cca.2020.05.044. Epub 2020 May 29.
8
Remdesivir for severe covid-19: a clinical practice guideline.瑞德西韦治疗严重 COVID-19:临床实践指南。
BMJ. 2020 Jul 30;370:m2924. doi: 10.1136/bmj.m2924.
9
Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?新冠疫情:在完整数据尚未公开时,医生是否应推荐治疗方法和疫苗?
BMJ. 2020 Aug 24;370:m3260. doi: 10.1136/bmj.m3260.
10
Children in Critical Care Due to Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Experience in a Spanish Hospital.因严重急性呼吸综合征冠状病毒 2 感染而入住重症监护病房的儿童:一家西班牙医院的经验。
Pediatr Crit Care Med. 2020 Aug;21(8):e576-e580. doi: 10.1097/PCC.0000000000002475.

引用本文的文献

1
First insight into eosinophils as a biomarker for the early distinction of COVID-19 from influenza A in outpatients.对嗜酸性粒细胞作为门诊患者中早期区分新冠肺炎与甲型流感生物标志物的首次洞察。
Exp Ther Med. 2025 Jan 22;29(3):56. doi: 10.3892/etm.2025.12806. eCollection 2025 Mar.
2
Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review.《2019冠状病毒病指南质量及推荐意见变化分析:一项系统评价》
Health Data Sci. 2021 Jul 22;2021:9806173. doi: 10.34133/2021/9806173. eCollection 2021.
3
Fine-Grained Assessment of COVID-19 Severity Based on Clinico-Radiological Data Using Machine Learning.基于临床和影像学数据的机器学习对 COVID-19 严重程度的精细评估。
Int J Environ Res Public Health. 2022 Aug 26;19(17):10665. doi: 10.3390/ijerph191710665.
4
"MATH+" Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale.“MATH+”新冠病毒感染多模式医院治疗方案:临床与科学依据
J Clin Med Res. 2022 Feb;14(2):53-79. doi: 10.14740/jocmr4658. Epub 2022 Feb 24.
5
Administration of Parenteral Vitamin C in Patients With Severe Infection: Protocol for a Systematic Review and Meta-analysis.严重感染患者肠外维生素C的应用:系统评价与Meta分析方案
JMIR Res Protoc. 2022 Jan 6;11(1):e33989. doi: 10.2196/33989.
6
Discordant and inappropriate discordant recommendations in consensus and evidence based guidelines: empirical analysis.共识和循证指南中的不一致和不恰当的不一致建议:实证分析。
BMJ. 2021 Nov 25;375:e066045. doi: 10.1136/bmj-2021-066045.
7
International alliance and AGREE-ment of 71 clinical practice guidelines on the management of critical care patients with COVID-19: a living systematic review.国际联盟和 71 项关于 COVID-19 重症监护患者管理的临床实践指南的 AGREE 协议:一项实时系统评价。
J Clin Epidemiol. 2022 Feb;142:333-370. doi: 10.1016/j.jclinepi.2021.11.010. Epub 2021 Nov 14.
8
Critical Review of the Scientific Evidence and Recommendations in COVID-19 Management Guidelines.对新冠疫情管理指南中科学证据和建议的批判性综述
Open Forum Infect Dis. 2021 Jul 14;8(8):ofab376. doi: 10.1093/ofid/ofab376. eCollection 2021 Aug.
9
Quality of and Recommendations for Relevant Clinical Practice Guidelines for COVID-19 Management: A Systematic Review and Critical Appraisal.新型冠状病毒肺炎管理相关临床实践指南的质量与推荐意见:一项系统评价与批判性评估
Front Med (Lausanne). 2021 Jun 10;8:630765. doi: 10.3389/fmed.2021.630765. eCollection 2021.
10
Convalescent Plasma Transfusion for the Treatment of COVID-19 in Adults: A Global Perspective.成人新冠病毒肺炎康复期血浆治疗的全球视角
Viruses. 2021 May 7;13(5):849. doi: 10.3390/v13050849.

本文引用的文献

1
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.羟氯喹在美国 COVID-19 住院患者中的使用效果。
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
2
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.基于其他严重呼吸道病毒感染的证据评估恢复期血浆治疗严重 COVID-19 的疗效和安全性:系统评价和荟萃分析。
CMAJ. 2020 Jul 6;192(27):E745-E755. doi: 10.1503/cmaj.200642. Epub 2020 May 22.
3
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.与 SARS-CoV-2 感染住院非重症患者病毒持续排出相关因素及洛匹那韦/利托那韦治疗的影响。
Eur Respir J. 2020 Jul 16;56(1). doi: 10.1183/13993003.00799-2020. Print 2020 Jul.
4
Adjuvant corticosteroid therapy for critically ill patients with COVID-19.COVID-19重症患者的辅助性皮质类固醇治疗
Crit Care. 2020 May 19;24(1):241. doi: 10.1186/s13054-020-02964-w.
5
Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.基于 COVID-19、其他冠状病毒感染、流感、社区获得性肺炎和急性呼吸窘迫综合征的证据评估 COVID-19 中皮质类固醇的疗效和安全性:系统评价和荟萃分析。
CMAJ. 2020 Jul 6;192(27):E756-E767. doi: 10.1503/cmaj.200645. Epub 2020 May 14.
6
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.法匹拉韦治疗新型冠状病毒肺炎的实验性治疗:一项开放标签对照研究。
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
7
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.美国传染病学会关于2019冠状病毒病患者治疗与管理的指南
Clin Infect Dis. 2020 Apr 27. doi: 10.1093/cid/ciaa478.
8
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.武汉成人 COVID-19 住院患者严重程度和死亡率的危险因素。
J Allergy Clin Immunol. 2020 Jul;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006. Epub 2020 Apr 12.
9
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).拯救脓毒症运动:2019 冠状病毒病(COVID-19)危重症成人管理指南。
Intensive Care Med. 2020 May;46(5):854-887. doi: 10.1007/s00134-020-06022-5. Epub 2020 Mar 28.
10
Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.在大流行期间治疗新冠病毒病——超说明书用药、同情用药及随机临床试验
JAMA. 2020 May 19;323(19):1897-1898. doi: 10.1001/jama.2020.4742.

Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline.

作者信息

Ye Zhikang, Rochwerg Bram, Wang Ying, Adhikari Neill K, Murthy Srinivas, Lamontagne François, Fowler Robert A, Qiu Haibo, Wei Li, Sang Ling, Loeb Mark, Shen Ning, Huang Minhua, Jiang Zhaonan, Arabi Yaseen M, Colunga-Lozano Luis Enrique, Jiang Li, Koh Younsuck, Liu Dong, Liu Fang, Phua Jason, Shen Aizong, Huo Tianyi, Du Bin, Zhai Suodi, Guyatt Gordon H

机构信息

Department of Health Research Methods, Evidence and Impact Canada (Ye, Rochwerg, Guyatt, Colunga-Lozano) and of Medicine (Rochwerg), McMaster University, Hamilton, Ont.; Department of Pharmacy (Wang), Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; Department of Medicine, Interdepartmental Division of Critical Care Medicine (Adhikari, Fowler), University of Toronto, Toronto, Ont.; Department of Critical Care Medicine and Sunnybrook Research Institute (Adhikari, Fowler), Sunnybrook Health Sciences Centre, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC; Department of Medicine (Lamontagne), Université de Sherbrooke; Centre de recherche du CHUS de Sherbrooke (Lamontagne), Sherbrooke, Que.; Department of Critical Care Medicine (Qiu), Zhongda hospital, School of Medicine, Southeast University, Nanjing, China; Department of Pharmacy (Wei), the First Affiliated Hospital of Guangzhou University of Medical; Department of Critical Care Medicine (Sang), the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou, China; Department of Pathology and Molecular Medicine and Health Research Methods, Evidence, and Impact (Loeb), McMaster University, Hamilton, Ont.; Department of Respiratory and Critical Care Medicine (Shen), Peking University Third Hospital, Beijing, China; Guangdong kuaiwen information technology co. LTD (Huang), Guanzhong, China; Kunshan Guanghui Precise Metal Co. Ltd. (Jiang), Kunshan, China; Intensive Care Department (Arabi), King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia; Department of Clinical Medicine (Colunga-Lozano), Health Science Center, Universidad de Guadalajara, Guadalajara, Mexico; Department of Critical Care Medicine (Jiang), Xuanwu Hospital, Capital Medical School, Beijing, China; Department of Pulmonary and Critical Care Medicine (Koh), University of Ulsan College of Medicine, Seoul, South Korea; Department of Pharmacy (Liu), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Department of Pharmacy (Liu, Zhai), Peking University Third Hospital, Beijing, China; Fast and Chronic Programmes (Phua), Alexandra Hospital, National University Health System, Singapore; Department of Pharmacy, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei (Shen), Anhui, China; General Surgery Department (Huo), Peking University Third Hospital, Beijing, China; Medical Intensive Care Unit (Du), Peking Union Medical College Hospital, Beijing.

Department of Health Research Methods, Evidence and Impact Canada (Ye, Rochwerg, Guyatt, Colunga-Lozano) and of Medicine (Rochwerg), McMaster University, Hamilton, Ont.; Department of Pharmacy (Wang), Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; Department of Medicine, Interdepartmental Division of Critical Care Medicine (Adhikari, Fowler), University of Toronto, Toronto, Ont.; Department of Critical Care Medicine and Sunnybrook Research Institute (Adhikari, Fowler), Sunnybrook Health Sciences Centre, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC; Department of Medicine (Lamontagne), Université de Sherbrooke; Centre de recherche du CHUS de Sherbrooke (Lamontagne), Sherbrooke, Que.; Department of Critical Care Medicine (Qiu), Zhongda hospital, School of Medicine, Southeast University, Nanjing, China; Department of Pharmacy (Wei), the First Affiliated Hospital of Guangzhou University of Medical; Department of Critical Care Medicine (Sang), the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou, China; Department of Pathology and Molecular Medicine and Health Research Methods, Evidence, and Impact (Loeb), McMaster University, Hamilton, Ont.; Department of Respiratory and Critical Care Medicine (Shen), Peking University Third Hospital, Beijing, China; Guangdong kuaiwen information technology co. LTD (Huang), Guanzhong, China; Kunshan Guanghui Precise Metal Co. Ltd. (Jiang), Kunshan, China; Intensive Care Department (Arabi), King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia; Department of Clinical Medicine (Colunga-Lozano), Health Science Center, Universidad de Guadalajara, Guadalajara, Mexico; Department of Critical Care Medicine (Jiang), Xuanwu Hospital, Capital Medical School, Beijing, China; Department of Pulmonary and Critical Care Medicine (Koh), University of Ulsan College of Medicine, Seoul, South Korea; Department of Pharmacy (Liu), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Department of Pharmacy (Liu, Zhai), Peking University Third Hospital, Beijing, China; Fast and Chronic Programmes (Phua), Alexandra Hospital, National University Health System, Singapore; Department of Pharmacy, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei (Shen), Anhui, China; General Surgery Department (Huo), Peking University Third Hospital, Beijing, China; Medical Intensive Care Unit (Du), Peking Union Medical College Hospital, Beijing

出版信息

CMAJ. 2020 May 19;192(20):E536-E545. doi: 10.1503/cmaj.200648. Epub 2020 Apr 29.

DOI:10.1503/cmaj.200648
PMID:32350002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7241888/
Abstract
摘要